Inhibitory profiles of captopril on matrix metalloproteinase-9 activity

European Journal of Pharmacology

Volumn 588, Issue 2-3, 2008, Pages 277-279

  Yamamoto, Daisuke ^a   Takai, Shinji ^a   Miyazaki, Mizuo ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

ACE (angiotensin converting enzyme) inhibitor; Enzyme activation; Inhibitory specificity; Matrix metalloproteinase 9; Molecular structure; Myocardial infarction

Indexed keywords

CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; GELATINASE B; IMIDAPRIL; LISINOPRIL;

ACUTE HEART INFARCTION; ARTICLE; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME BINDING; ENZYME BLOOD LEVEL; ENZYME INHIBITION; HUMAN; MOLECULAR INTERACTION; MOLECULAR MODEL; PRIORITY JOURNAL;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BINDING SITES; CAPTOPRIL; HUMANS; HYDROPHOBICITY; MATRIX METALLOPROTEINASE 9; MODELS, MOLECULAR;

EID: 44649197091     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.04.031     Document Type: Article

References (16)

1. Blood Pressure Lowering Treatment Trialists' Collaboration, Turnbull F., Neal B., Pfeffer M., Kostis J., Algert C., Woodward M., Chalmers J., Zanchetti A., and MacMahon S. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J. Hypertens. 25 (2007) 951-958
2. 92 bonds of the catalytic domain. J. Biol. Chem. 272 (1997) 25628-25635
3. Furubayashi K., Takai S., Jin D., Muramatsu M., Ibaraki T., Nishimoto M., Fukumoto H., Katsumata T., and Miyazaki M. The significance of chymase in the progression of abdominal aortic aneurysms in dogs. Hypertens. Res. 30 (2007) 349-357
4. Jin D., Takai S., Yamada M., Sakaguchi M., and Miyazaki M. Beneficial effects of cardiac chymase inhibition during the acute phase of myocardial infarction. Life Sci. 71 (2002) 437-446
5. Jin Y., Han H.C., and Lindsey M.L. ACE inhibitors to block MMP-9 activity: new functions for old inhibitors. J. Mol. Cell. Cardiol. 43 (2007) 664-666
6. Kai H., Ikeda H., Yasukawa H., Kai M., Seki Y., Kuwahara F., Ueno T., Sugi K., and Imaizumi T. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J. Am. Coll. Cardiol. 32 (1998) 368-372
7. Kim H.M., Shin D.R., Yoo O.J., Lee H., and Lee J.O. Crystal structure of Drosophila angiotensin I-converting enzyme bound to captopril and lisinopril. FEBS Lett. 538 (2003) 65-70
8. Lindsey M.L., Gannon J., Aikawa M., Schoen F.J., Rabkin E., Lopresti-Morrow L., Crawford J., Black S., Libby P., Mitchell P.G., and Lee R.T. Selective matrix metalloproteinase inhibition reduces left ventricular remodeling but does not inhibit angiogenesis after myocardial infarction. Circulation 105 (2002) 753-758
9. Lindsey M.L., Escobar G.P., Dobrucki L.W., Goshorn D.K., Bouges S., Mingoia J.T., McClister Jr. D.M., Su H., Gannon J., MacGillivray C., Lee R.T., Sinusas A.J., and Spinale F.G. Matrix metalloproteinase-9 gene deletion facilitates angiogenesis after myocardial infarction. Am. J. Physiol. Heart Circ. Physiol. 290 (2006) H232-H239
10. Natesh R., Schwager S.L., Evans H.R., Sturrock E.D., and Acharya K.R. Structural details on the binding of antihypertensive drugs captopril and enalaprilat to human testicular angiotensin I-converting enzyme. Biochemistry 43 (2004) 8718-8724
11. Okada Y., Gonoji Y., Naka K., Tomita K., Nakanishi I., Iwata K., Yamashita K., and Hayakawa T. Matrix metalloproteinase 9 (92-kDa gelatinase/type IV collagenase) from HT 1080 human fibrosarcoma cells. Purification and activation of the precursor and enzymic properties. J. Biol. Chem. 267 (1992) 21712-21719
12. Rowsell S., Hawtin P., Minshull C.A., Jepson H., Brockbank S.M., Barratt D.G., Slater A.M., McPheat W.L., Waterson D., Henney A.M., and Pauptit R.A. Crystal structure of human MMP9 in complex with a reverse hydroxamate inhibitor. J. Mol. Biol. 319 (2002) 173-181
13. Takai S., Yamamoto D., Jin D., Inagaki S., Yoshikawa K., Tanaka K., and Miyazaki M. Inhibition of matrix metalloproteinase-9 activity by lisinopril after myocardial infarction in hamsters. Eur. J. Pharmacol. 568 (2007) 231-233
14. Yamamoto D., Takai S., and Miyazaki M. Prediction of interaction mode between a typical ACE inhibitor and MMP-9 active site. Biochem. Biophys. Res. Commun. 354 (2007) 981-984
15. Yamamoto D., Takai S., Jin D., Inagaki S., Tanaka K., and Miyazaki M. Molecular mechanism of imidapril for cardiovascular protection via inhibition of MMP-9. J. Mol. Cell. Cardiol. 43 (2007) 670-676
16. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., and Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 342 (2000) 145-153